EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast

Modern Pathology

Volumn 23, Issue 5, 2010, Pages 644-653

  Vranic, Semir ^a,b   Tawfik, Ossama ^c   Palazzo, Juan ^d   Bilalovic, Nurija ^b   Eyzaguirre, Eduardo ^e   Lee, Lisa Mj ^a   Adegboyega, Patrick ^e   Hagenkord, Jill ^a   Gatalica, Zoran ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Apocrine carcinoma; Breast; Gene amplification; HER 1 EGFR; HER 2 neu; Polysomy

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; APOCRINE CARCINOMA; APOCRINE GLAND; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE AMPLIFICATION; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MORPHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RECEPTORS, STEROID; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 77952009500     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.50     Document Type: Article

References (49)

1. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology 2008;52:3-10.
2. Celis JE, Gromova I, Gromov P, et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett 2006;580:2935-2944.
3. Tavassoli FA, Devilee P, (eds). World Health Organization Classificaiton of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003.
4. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 1997;193:753-758.
5. Tavassoli FA, Purcell CA, Bratthauer GL, et al. Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J 1996;2:261-269.
6. Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum Pathol 2001;32:487-493.
7. Masood S, Rosa M. The challenge of apocrine proliferations of the breast: a morphologic approach. Pathol Res Pract 2009;205:155-164.
8. Celis JE, Cabezon T, Moreira JM, et al. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a welldefined cohort. Mol Oncol 2009;3:220-237.
9. Nicolás Díaz-Chico B, Germán Rodríguez F, González A, et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007;105:1-15.
10. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993;170:31-35.
11. Bratthauer GL, Lininger RA, Man YH, et al. Androgen and estrogen receptor mRNA status in apocrine carcinomas. Diagn Mol Pathol 2002;11:113-118.
12. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas. Cancer 2003;98:703-711.
13. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-4671.
14. Doane AS, Danso M, Lal P, et al. An estrogen receptornegative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008.
15. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:404.
16. Sanga S, Broom BM, Cristini V, et al. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BM Med Genomics 2009;2:59.
17. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and erbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008;10:542-548.
18. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-150.
19. Kaya H, Bozkurt SU, Erbarut I, et al. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. Pathol Res Pract 2008;204:367-371.
20. Matsuo K, Fukutomi T, Hasegawa T, et al. Histological and immunohistochemical analysis of apocrine breast carcinoma. Breast Cancer 2002;9:43-49.
21. Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006;11:3-11.
22. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869-4874.
23. Honma N, Sakamoto G, Akiyama F, et al. Breast carcinoma in women over the age of 85: distinct histological pattern an androgen, oestrogen, and progesterone receptor status. Histopathology 2003;42:120-127.
24. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
25. Krishnamurti U, Hammers JL, Atem FD, et al. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 2009;22:1044-1048.
26. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and Path-Vysion FISH assay. Am J Clin Pathol 2004;121:70-77.
27. Lyons-Weiler M, Hagenkord J, Sciulli CM, et al. Optimization of the Affymetrix GeneChip mapping 10 K 2.0 assay for routine clinical use on formalin fixed paraffin embedded tissues. Diagn Mol Pathol 2008;17:3-13.
28. Monzon FA, Hagenkord J, Lyons-Weiler M, et al. Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol 2008;21:599-608.
29. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
30. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
31. Perou CM, SØrlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
32. Moe RE, Anderson BO. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol 2007;95:437-439.
33. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120:725-731.
34. Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
35. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-1333.
36. Varga Z, Zhao J, Öhlschlegel C, et al. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 2004;44:332-338.
37. Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009;2:444-455.
38. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 2008;21:1271-1277.
39. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109-114.
40. Wang S, Saboorian MH, Frenkel EP, et al. Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2002;15:137-145.
41. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009;22:1169-1175.
42. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev Cancer 2005;5:341-354.
43. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009;15:1133-1139.
44. Bhargava R, Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005;18:1027-1033.
45. Park K, Han S, Shin E, et al. EGFR gene and protein expression in breast cancers. Euro J Surg Oncol 2007;33:956-960.
46. Corzo C, Tusquets I, Salido M, et al. Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry. Tumour Biol 2005;26:25-30.
47. Kapranos N, Kounelis S, Karantasis H, et al. Numerical aberrations of chromosomes 1 and 7 by fluorescent in situ hybridization and DNA ploidy analysis in breast cancer. Breast J 2005;11:448-453.
48. Sauer T, Beraki K, Jebsen PW, et al. Numerical abnormalities of chromosome 7 in interphase cell nuclei of breast carcinoma have no impact on immunohistochemically determined EGFR status. AP-MIS 1999;107:211-216.
49. Gwin K, Lezon-Geyda K, Harris L, et al. Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation. Int J Surg Pathol 2009; doi:10.1177/1066896909334127